CA2514733A1 - Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen - Google Patents

Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen Download PDF

Info

Publication number
CA2514733A1
CA2514733A1 CA002514733A CA2514733A CA2514733A1 CA 2514733 A1 CA2514733 A1 CA 2514733A1 CA 002514733 A CA002514733 A CA 002514733A CA 2514733 A CA2514733 A CA 2514733A CA 2514733 A1 CA2514733 A1 CA 2514733A1
Authority
CA
Canada
Prior art keywords
crystal
acid
degrees
ray diffraction
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002514733A
Other languages
English (en)
French (fr)
Inventor
Oern Almarsson
Magali Bourghol Hickey
Matthew Peterson
Brian Moulton
Nair Rodriguez-Hornedo
Michael J. Zaworotko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
University of Michigan
Transform Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/006662 external-priority patent/WO2003074474A2/en
Priority claimed from US10/449,307 external-priority patent/US7078526B2/en
Priority claimed from PCT/US2003/019574 external-priority patent/WO2004000284A1/en
Priority claimed from PCT/US2003/027772 external-priority patent/WO2004078161A1/en
Priority claimed from US10/660,202 external-priority patent/US7927613B2/en
Priority claimed from PCT/US2003/041273 external-priority patent/WO2004061433A1/en
Application filed by Individual filed Critical Individual
Publication of CA2514733A1 publication Critical patent/CA2514733A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
CA002514733A 2003-02-28 2004-02-26 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen Abandoned CA2514733A1 (en)

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
US45121303P 2003-02-28 2003-02-28
US60/451,213 2003-02-28
USPCT/US03/06662 2003-03-03
PCT/US2003/006662 WO2003074474A2 (en) 2002-03-01 2003-03-03 Multiple-component solid phases containing at least one active pharmaceutical ingredient
US45602703P 2003-03-18 2003-03-18
US60/456,027 2003-03-18
US46396203P 2003-04-18 2003-04-18
US60/463,962 2003-04-18
US10/449,307 2003-05-30
US10/449,307 US7078526B2 (en) 2002-05-31 2003-05-30 CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
PCT/US2003/019574 WO2004000284A1 (en) 2002-06-21 2003-06-20 Pharmaceutical compositions with improved dissolution
USPCT/US03/19574 2003-06-20
US10/601,092 2003-06-20
US10/601,092 US20050025791A1 (en) 2002-06-21 2003-06-20 Pharmaceutical compositions with improved dissolution
US48706403P 2003-07-11 2003-07-11
US60/487,064 2003-07-11
USPCT/US03/27772 2003-09-04
PCT/US2003/027772 WO2004078161A1 (en) 2003-02-28 2003-09-04 Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US10/660,202 US7927613B2 (en) 2002-02-15 2003-09-11 Pharmaceutical co-crystal compositions
US10/660,202 2003-09-11
US50820803P 2003-10-02 2003-10-02
US60/508,208 2003-10-02
PCT/US2003/041273 WO2004061433A1 (en) 2002-12-30 2003-12-24 Pharmaceutical compositions with improved dissolution
USPCT/US03/41273 2003-12-24
US54275204P 2004-02-06 2004-02-06
US60/542,752 2004-02-06
PCT/US2004/006288 WO2004078163A2 (en) 2003-02-28 2004-02-26 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen

Publications (1)

Publication Number Publication Date
CA2514733A1 true CA2514733A1 (en) 2004-09-16

Family

ID=56290526

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002514733A Abandoned CA2514733A1 (en) 2003-02-28 2004-02-26 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen

Country Status (4)

Country Link
EP (1) EP1631260A2 (ja)
JP (1) JP2007524596A (ja)
CA (1) CA2514733A1 (ja)
WO (1) WO2004078163A2 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883713B2 (en) 2001-06-22 2011-02-08 Aicuris Gmbh & Co. Kg Topical application of thiazolyl amides
US7935817B2 (en) 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
US8784887B2 (en) 2005-03-30 2014-07-22 Aicuris Gmbh & Co. Kg Pharmaceutical preparation of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide

Families Citing this family (391)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
JP4906233B2 (ja) 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ 少なくとも１種の有効薬剤成分を含有する多構成要素固相
EP1511490A4 (en) * 2002-05-31 2009-03-11 Transform Pharmaceuticals Inc NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
JP4842819B2 (ja) * 2003-09-04 2011-12-21 セフアロン・インコーポレーテツド モダフィニル組成物
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
EP1765379A4 (en) * 2004-06-17 2009-05-27 Transform Pharmaceuticals Inc CO-CRISTAL PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
US20100221327A1 (en) * 2005-06-15 2010-09-02 Elan Pharma International Limited Nanoparticulate azelnidipine formulations
US20070099237A1 (en) * 2005-10-31 2007-05-03 The Regents Of The University Of Michigan Reaction co-crystallization of molecular complexes or co-crystals
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US8163790B2 (en) 2005-12-08 2012-04-24 New Form Pharmaceuticals, Inc. Metronidazole cocrystals and imipramine cocrystals
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
US20080132419A1 (en) * 2006-10-04 2008-06-05 Nair Rodriguez-Hornedo Dissolution and precipitation of cocrystals with ionizable components
CA2666159A1 (en) * 2006-10-10 2008-05-29 Janssen Pharmaceutica Nv Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
AU2007319141B2 (en) 2006-11-17 2013-01-10 Supernus Pharmaceuticals Inc. Sustained-release formulations of topiramate
TW200901889A (en) 2007-02-09 2009-01-16 Basf Se Crystalline complexes of agriculturally active organic compounds
WO2008108639A1 (en) * 2007-03-08 2008-09-12 Avantium Holding B.V. Co-crystalline forms of carbamazepine
EP2167043A4 (en) * 2007-06-06 2013-05-01 Univ South Florida NEW USE CO-CRYSTAL COMPOSITIONS
US8124603B2 (en) 2008-01-22 2012-02-28 Thar Pharmaceuticals In vivo studies of crystalline forms of meloxicam
US8003700B2 (en) * 2008-04-07 2011-08-23 Mutual Pharamaceutical Company, Inc. Colchicine solid complex; methods of making; and methods of use thereof
US8519002B2 (en) 2008-04-07 2013-08-27 Takeda Pharmaceuticals U.S.A., Inc. Colchicine solid complex; methods of making; and methods of use thereof
WO2009140466A2 (en) * 2008-05-14 2009-11-19 Dr. Reddy's Laboratories Ltd. Linezolid co-crystals
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
US20110275695A1 (en) * 2008-06-13 2011-11-10 Bionevia Pharmaceuticals, Inc. Crystalline forms of zotepine hydrochloride
WO2010002675A2 (en) 2008-06-30 2010-01-07 Mutual Pharmaceutical Company, Inc. Quinine sulfate/bisulfate solid complex; methods of making; and methods of use thereof
US8697735B2 (en) 2008-07-25 2014-04-15 Bionevia Pharmaceuticals, Inc. Solid forms of epalrestat
GB0813709D0 (en) * 2008-07-26 2008-09-03 Univ Dundee Method and product
EP2361247A4 (en) * 2008-08-06 2012-08-08 Bionevia Pharmaceuticals Inc FLUPIRTINHYDROCHLORID-maleic acid co-crystal
US8906948B2 (en) 2008-09-06 2014-12-09 Bionevia, LLC Choline cocrystal of epalrestat
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
EP2199274A1 (en) * 2008-12-16 2010-06-23 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and paracetamol
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
WO2010085589A2 (en) 2009-01-22 2010-07-29 G&H Brands Llc Desensitizing drug product
KR20100091127A (ko) * 2009-02-09 2010-08-18 주식회사 한독약품 아데포비어 디피복실의 신규한 염 및 그의 제조방법
JP5558875B2 (ja) * 2009-03-19 2014-07-23 日本曹達株式会社 新規包接錯体、エポキシ樹脂組成物及び半導体封止用エポキシ樹脂組成物
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
KR20120036850A (ko) 2009-05-15 2012-04-18 노파르티스 아게 알도스테론 신타제 억제제로서의 벤족사졸론 유도체
SI2429995T1 (sl) 2009-05-15 2014-05-30 Novartis Ag Arilpiridini kot inhibitorji aldosteron sintaze
US20120129923A1 (en) * 2009-05-20 2012-05-24 Nutracryst Therapeutics Private Limited Pharmaceutical co-crystals of quercetin
DK2435409T3 (da) 2009-05-28 2014-10-27 Novartis Ag Substituerede aminopropionsyrederivater som neprilysininhibitorer
EA201101672A1 (ru) 2009-05-28 2012-06-29 Новартис Аг Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
AR077490A1 (es) 2009-07-21 2011-08-31 Novartis Ag Composiciones farmaceuticas topicas para el tratamiento de una condicion hiperproliferativa de la piel
AR077328A1 (es) 2009-07-24 2011-08-17 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
EP2459176B1 (en) 2009-07-31 2017-09-27 Grünenthal GmbH Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP2281558A1 (en) * 2009-08-06 2011-02-09 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compounds of O-Desmethyl-Tramadol and COX-inhibitors
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
EP2467383A1 (en) 2009-08-20 2012-06-27 Novartis AG Heterocyclic oxime compounds
EA201200321A1 (ru) 2009-08-26 2012-09-28 Новартис Аг Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4
WO2011026911A1 (en) 2009-09-04 2011-03-10 Novartis Ag Bipyridines useful for the treatment of proliferative diseases
BR112012008147A2 (pt) 2009-09-04 2016-03-01 Novartis Ag compostos heteroarílicos como inibidores da quinase
IN2012DN01273A (ja) 2009-09-04 2015-05-15 Novartis Ag
MX2012003007A (es) 2009-09-10 2012-04-11 Novartis Ag Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.
CN102596963A (zh) 2009-09-10 2012-07-18 诺瓦提斯公司 二环杂芳基的醚衍生物
EP2325172A1 (en) * 2009-11-02 2011-05-25 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of celecoxib and L-proline
AU2010317167B2 (en) 2009-11-04 2012-11-29 Novartis Ag Heterocyclic sulfonamide derivatives useful as MEK inhibitors
ES2663351T3 (es) 2009-11-17 2018-04-12 Novartis Ag Derivados de aril-piridina como inhibidores de la aldosterona sintasa
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
ES2472446T3 (es) 2009-11-30 2014-07-01 Novartis Ag Derivados de imidazol como inhibidores de aldosterona sintasa
WO2011073316A1 (en) 2009-12-18 2011-06-23 Novartis Ag 4-aryl-butane-1,3-diamides
JP2013515032A (ja) 2009-12-21 2013-05-02 ノバルティス アーゲー 二置換ヘテロアリール縮合ピリジン類
CN102762567A (zh) 2009-12-21 2012-10-31 诺瓦提斯公司 作为食欲肽受体拮抗剂的二氮杂-螺[5.5]十一烷类
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
PT2519515E (pt) 2009-12-31 2014-02-17 Novartis Ag Derivados de pirazina e sua utilizaçâo no tratamento de distúrbios neurológicos
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
US8399712B2 (en) 2010-02-03 2013-03-19 Laurus Labs Private Limited Pterostilbene cocrystals
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
WO2011158110A2 (en) * 2010-04-28 2011-12-22 Nuformix Limited Cilostazol cocrystals and compositions
US20130053381A1 (en) 2010-05-20 2013-02-28 Novartis Ag 2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl-sulfonamide derivatives
CN102947275A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 哌啶基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
WO2011157787A1 (en) 2010-06-17 2011-12-22 Novartis Ag Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
TWI421250B (zh) 2010-07-13 2014-01-01 Novartis Ag 衍生物及其用於治療神經性疾病之用途
RS55856B1 (sr) 2010-07-14 2017-08-31 Novartis Ag Heterociklična jedinjenja agonisti ip receptora
MX2013000906A (es) 2010-07-22 2013-02-27 Novartis Ag Compuestos de tiofeno 2, 3, 5-trisustituidos y usos de los mismos.
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
MX2013002864A (es) 2010-09-13 2013-08-29 Novartis Ag Triazina-oxadiazoles.
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2619208B1 (en) 2010-09-20 2016-11-09 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
CA2811799A1 (en) 2010-10-08 2012-04-12 Novartis Ag Vitamin e formulations of sulfamide ns3 inhibitors
US20120101110A1 (en) 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
WO2012080260A1 (en) 2010-12-13 2012-06-21 Novartis Ag Dimeric iap inhibitors
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
EP2655368A1 (en) 2010-12-20 2013-10-30 Irm Llc Compositions and methods for modulating farnesoid x receptors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2655369A1 (en) 2010-12-20 2013-10-30 Irm Llc Compositions and methods for modulating farnesoid x receptors
WO2012084873A1 (en) 2010-12-20 2012-06-28 Novartis Ag 4- (hetero) aryl - ethynyl - octahydro - indole - 1 - carboxylic acid esters
US20120165331A1 (en) 2010-12-22 2012-06-28 Sangamesh Badiger Di/tri-aza-spiro-C9-C11alkanes
ES2647664T3 (es) 2011-01-04 2017-12-26 Novartis Ag Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (AMD)
CN103429589A (zh) 2011-01-12 2013-12-04 诺瓦提斯公司 噁嗪衍生物及其在治疗神经障碍中的用途
PL2663561T3 (pl) 2011-01-13 2016-10-31 Nowe pochodne heterocykliczne i ich zastosowanie w leczeniu zaburzeń neurologicznych
CA2824493A1 (en) 2011-01-13 2012-07-19 Novartis Ag Bace-2 inhibitors for the treatment of metabolic disorders
WO2012098501A1 (en) * 2011-01-21 2012-07-26 Ranbaxy Laboratories Limited Febuxostat co-crystals
US9067881B2 (en) 2011-01-24 2015-06-30 Novartis Ag 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
WO2012101065A2 (en) 2011-01-28 2012-08-02 Novartis Ag Pyrimidine biaryl amine compounds and their uses
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
CA2825605C (en) 2011-01-31 2019-05-07 Novartis Ag Heterocyclic derivatives
WO2012104823A2 (en) 2011-02-04 2012-08-09 Novartis Ag Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
PE20140378A1 (es) 2011-02-25 2014-03-28 Irm Llc Compuestos y composiciones como inhibidores de la trk
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
CN103492390A (zh) 2011-03-08 2014-01-01 诺瓦提斯公司 氟苯基双环杂芳基化合物
JP2014508814A (ja) 2011-03-24 2014-04-10 ユニバーシティ・オブ・サウス・フロリダ リチウム組成物
US8748435B2 (en) 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
EP2697240B1 (en) 2011-04-14 2015-09-16 Novartis AG Glycoside derivatives and uses thereof
PL2517700T3 (pl) 2011-04-28 2013-12-31 Zentiva Ks Farmaceutyczne dopuszczalne kokryształy n-[2-(7-metoksy-1-naftylo]acetamidu i sposoby ich wytwarzania
UY34072A (es) 2011-05-17 2013-01-03 Novartis Ag Derivados sustituidos de indol
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
EP2729466B1 (en) 2011-07-08 2015-08-19 Novartis AG Novel pyrrolo pyrimidine derivatives
CN103764635B (zh) 2011-07-08 2016-01-20 诺华股份有限公司 新的三氟甲基-噁二唑衍生物及其在疾病治疗中的用途
KR20140056258A (ko) 2011-07-08 2014-05-09 노파르티스 아게 높은 트리글리세리드 대상체에서의 아테롬성동맥경화증의 치료 방법
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
CN103857678A (zh) 2011-07-27 2014-06-11 诺华股份有限公司 吡唑啉衍生物及其用作选择性雄激素受体调节剂的用途
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
EP2751105A1 (en) 2011-09-01 2014-07-09 Irm Llc Compounds and compositions as c-kit kinase inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
KR20140071383A (ko) 2011-09-01 2014-06-11 아이알엠 엘엘씨 C-kit 키나제 억제제로서의 화합물 및 조성물
CA2845169C (en) 2011-09-01 2022-04-19 Irm Llc Compounds and compositions as c-kit kinase inhibitors
WO2013033620A1 (en) 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as pdgfr kinase inhibitors
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
AR088256A1 (es) 2011-10-08 2014-05-21 Novartis Ag Derivados de carbamato / urea como antagonistas del receptor h3
IN2014DN03206A (ja) 2011-10-13 2015-05-22 Novartis Ag
TWI580442B (zh) 2011-10-19 2017-05-01 傑特大學 醫藥毫微懸浮物
JP2014530851A (ja) 2011-10-21 2014-11-20 ノバルティスアーゲー Ｐｉ３ｋモジュレータとしてのキナゾリン誘導体
PL2771342T3 (pl) 2011-10-28 2016-11-30 Nowe pochodne puryny i ich zastosowanie w leczeniu chorób
CN104159584A (zh) * 2011-11-25 2014-11-19 诺弗米克斯有限公司 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
JP5966014B2 (ja) 2011-11-28 2016-08-10 ノバルティス アーゲー 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の処置におけるその使用
JP5992054B2 (ja) 2011-11-29 2016-09-14 ノバルティス アーゲー ピラゾロピロリジン化合物
WO2013093850A1 (en) 2011-12-22 2013-06-27 Novartis Ag Quinoline derivatives
PL2794600T3 (pl) 2011-12-22 2018-06-29 Novartis Ag Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów
WO2013105058A1 (en) 2012-01-13 2013-07-18 Novartis Ag 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US9115129B2 (en) 2012-01-13 2015-08-25 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
AR089698A1 (es) 2012-01-13 2014-09-10 Novartis Ag Compuestos heterociclicos antagonistas del receptor ip
US20140357641A1 (en) 2012-01-13 2014-12-04 Novartis Ag IP receptor agonist heterocyclic compounds
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
WO2013111107A1 (en) 2012-01-27 2013-08-01 Novartis Ag Aminopyridine derivatives as plasma kallikrein inhibitors
EP2807157A1 (en) 2012-01-27 2014-12-03 Novartis AG 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
UY34646A (es) 2012-03-02 2013-10-31 Novartis Ag Compuestos de espirohidantoína y su uso como moduladores selectivos del receptor de andrógenos
EP2828262A4 (en) 2012-03-19 2015-09-23 Forum Pharmaceuticals Inc IMIDAZOTRIAZINONVERBINDUNGEN
US9108956B2 (en) 2012-04-27 2015-08-18 Novartis Ag Cyclic ether DGAT1 inhibitorscyclic ether DGAT1 inhibitors
JP6042529B2 (ja) 2012-04-27 2016-12-14 ノバルティス アーゲー 環式橋頭エーテルｄｇａｔ１阻害剤
WO2013164790A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
PE20150623A1 (es) 2012-05-04 2015-05-17 Novartis Ag Moduladores de la ruta del complemento y usos de los mismos
US20130310387A1 (en) 2012-05-16 2013-11-21 Novartis Ag Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
WO2013184766A1 (en) 2012-06-06 2013-12-12 Irm Llc Compounds and compositions for modulating egfr activity
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
EP2861589B1 (en) * 2012-06-15 2017-05-17 Basf Se Multicomponent crystals comprising dasatinib and selected cocrystal formers
EP2864322B1 (en) 2012-06-20 2016-04-27 Novartis AG Complement pathway modulators and uses thereof
CA2877030A1 (en) * 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
WO2014002053A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US9464081B2 (en) 2012-06-28 2016-10-11 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
ES2647124T3 (es) 2012-06-28 2017-12-19 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
JP6214647B2 (ja) 2012-06-28 2017-10-18 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
JP6273274B2 (ja) 2012-06-28 2018-01-31 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
CA2876993A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
EP2872503B1 (en) 2012-07-12 2018-06-20 Novartis AG Complement pathway modulators and uses thereof
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
KR101303803B1 (ko) 2012-08-02 2013-09-04 순천향대학교 산학협력단 반용매법에 의한 카바마제핀-사카린 공결정의 제조 방법 및 제조된 공결정을 포함하는 조성물
CN104520297B (zh) 2012-08-13 2016-08-24 瑞士诺华动物保健有限公司 作为肾酪氨酸激酶抑制剂的双环杂芳基环烷基二胺衍生物
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
EP2890687B1 (en) 2012-08-30 2017-06-28 Novartis AG Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
WO2014033630A1 (en) 2012-08-31 2014-03-06 Novartis Ag Novel aminothiazole carboxamides as kinase inhibitors
WO2014033617A1 (en) 2012-08-31 2014-03-06 Novartis Ag 2'-ethynyl nucleoside derivatives for treatment of viral infections
WO2014033631A1 (en) 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
US9447039B2 (en) 2012-09-07 2016-09-20 Novartis Ag Indole carboxamide derivatives and uses thereof
US9546173B2 (en) 2012-09-19 2017-01-17 Novartis Ag Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors
US20150216867A1 (en) 2012-09-25 2015-08-06 Novartis Ag Compounds for use in gastric complication
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
CN104603146B (zh) 2012-09-29 2018-01-02 诺华股份有限公司 环肽类化合物及其作为药物的用途
JP6243918B2 (ja) 2012-10-16 2017-12-06 トレロ ファーマシューティカルズ， インコーポレイテッド Ｐｋｍ２調節因子およびそれらの使用方法
CA2888194A1 (en) 2012-11-07 2014-05-15 Novartis Ag Substituted indole derivatives
US9296733B2 (en) * 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
ME03042B (me) 2012-11-19 2018-10-20 Novartis Ag Jedinjenja i kompozicije za tretman parazitskih oboljenja
WO2014078813A1 (en) 2012-11-19 2014-05-22 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
CN104837490B (zh) 2012-12-13 2017-10-03 诺华股份有限公司 作为无义突变抑制子的嘧啶并[4，5‑b]喹啉‑4，5(3H，10H)‑二酮
EA027988B1 (ru) 2012-12-13 2017-09-29 Новартис Аг Производные пиридона и их применение для лечения туберкулеза
US20140171404A1 (en) 2012-12-19 2014-06-19 Novartis Ag Autotaxin inhibitors
CA2895656A1 (en) 2012-12-19 2014-06-26 Novartis Ag Tricyclic compounds as cftr inhibitors
US20150336960A1 (en) 2012-12-19 2015-11-26 Novartis Ag Aryl-substituted fused bicyclic pyridazine compounds
EA201591177A1 (ru) 2012-12-19 2015-11-30 Новартис Аг Трициклические соединения для ингибирования канала cftr
EP2948451B1 (en) 2013-01-22 2017-07-12 Novartis AG Substituted purinone compounds
EP2948453B1 (en) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9040712B2 (en) 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
CN105189500A (zh) 2013-02-13 2015-12-23 诺华股份有限公司 Ip受体激动剂杂环化合物
HUE038248T2 (hu) 2013-02-14 2018-10-29 Novartis Ag Helyettesített biszfenil-bután-foszfonsav származékok, mint NEP (semleges endopeptidáz) inhibitorok
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
JP6230626B2 (ja) 2013-02-28 2017-11-15 ノバルティス アーゲー ベンゾチアゾロン化合物を含む製剤
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN105229003B (zh) 2013-03-14 2017-03-15 诺华股份有限公司 作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014160649A1 (en) 2013-03-29 2014-10-02 Novartis Ag Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections
WO2014167528A1 (en) 2013-04-11 2014-10-16 Novartis Ag Spiropyrazolopyridine derivatives and uses thereof for the treatment of viral infections
WO2014178040A1 (en) 2013-04-29 2014-11-06 Mapi Pharma Ltd. Co-crystals of dapagliflozin
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
WO2014191894A1 (en) 2013-05-27 2014-12-04 Novartis Ag Imidazopyrrolidinone derivatives and their use in the treatment of disease
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
AU2014272700B2 (en) 2013-05-28 2016-12-01 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
EA028175B1 (ru) 2013-05-28 2017-10-31 Новартис Аг Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
WO2015008230A1 (en) 2013-07-18 2015-01-22 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
WO2015008229A1 (en) 2013-07-18 2015-01-22 Novartis Ag Autotaxin inhibitors
KR20210130843A (ko) 2013-07-31 2021-11-01 노파르티스 아게 1,4-이치환된 피리다진 유사체 및 smn-결핍-관련 상태를 치료하기 위한 그의 용도
BR112016008276B1 (pt) 2013-10-25 2021-03-02 Novartis Ag derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica
CN105849090A (zh) 2013-10-30 2016-08-10 诺华股份有限公司 2-苄基-苯并咪唑补体因子b抑制剂及其用途
CU24425B1 (es) 2013-11-01 2019-06-04 Novartis Ag Amino-heteroaril-benzamidas como inhibidores de cinasa
WO2015066413A1 (en) 2013-11-01 2015-05-07 Novartis Ag Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
WO2015070177A2 (en) * 2013-11-11 2015-05-14 Collaborative Medicinal Development, Llc Metal complexes and methods of treatment
KR20160086930A (ko) 2013-11-21 2016-07-20 노파르티스 아게 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EP3753578A1 (en) 2013-12-17 2020-12-23 Novartis AG Cytotoxic peptides and conjugates thereof
TN2016000253A1 (en) 2013-12-19 2017-10-06 Novartis Ag [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis.
MX2016008247A (es) 2013-12-20 2016-10-21 Novartis Ag Derivados de acido heteroaril butanoico como inhibidores de lta4h.
WO2015102929A1 (en) 2013-12-30 2015-07-09 Novartis Ag Tricyclic sulfonamide derivatives
WO2015148379A1 (en) 2014-03-24 2015-10-01 Novartis Ag Monobactam organic compounds for the treatment of bacterial infections
EP3131893B1 (en) 2014-04-17 2020-02-12 Novartis AG Polycyclic herg activators
CN106573924B (zh) 2014-04-22 2019-06-25 诺华股份有限公司 作为LpxC抑制剂的异噁唑啉异羟肟酸衍生物
CN106458966B (zh) 2014-04-24 2019-05-07 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的吡嗪衍生物
CN106458980A (zh) 2014-04-24 2017-02-22 诺华股份有限公司 作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物
US20170037030A1 (en) 2014-04-24 2017-02-09 Novartis Ag Autotaxin inhibitors
MX2016013812A (es) 2014-04-24 2017-03-09 Novartis Ag Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
MY186570A (en) 2014-05-13 2021-07-27 Novartis Ag Compounds and compositions for inducing chondrogenesis
US20170088546A1 (en) 2014-05-14 2017-03-30 Novartis Ag Carboxamide inhibitors
US9403810B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
TW201623288A (zh) 2014-05-14 2016-07-01 諾華公司 甲醯胺衍生物
WO2015173656A1 (en) 2014-05-14 2015-11-19 Novartis Ag Carboxamide derivatives
CN106170489B (zh) 2014-05-28 2019-05-03 诺华股份有限公司 新的吡唑并嘧啶衍生物及其作为malt1抑制剂的用途
WO2015186061A1 (en) 2014-06-03 2015-12-10 Novartis Ag Pyridopyrimidinedione derivatives
CN106459041B (zh) 2014-06-03 2018-10-16 诺华股份有限公司 嘧啶并[4,5-b]喹啉-4,5(3H,10H)-二酮衍生物
TN2016000490A1 (en) 2014-06-03 2018-04-04 Novartis Ag Naphthyridinedione derivatives.
CN106573956A (zh) 2014-06-13 2017-04-19 诺华股份有限公司 澳瑞他汀衍生物及其缀合物
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625586A (zh) 2014-07-02 2016-07-16 諾華公司 環己烯－１－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625601A (zh) 2014-07-02 2016-07-16 諾華公司 噻吩－２－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
EP3177593A1 (en) 2014-08-06 2017-06-14 Novartis AG Quinolone derivatives as antibacterials
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
ES2844211T3 (es) 2014-09-12 2021-07-21 Novartis Ag Compuestos y composiciones en calidad de inhibidores de quinasa
US10167279B2 (en) 2014-09-12 2019-01-01 Novartis Ag Compounds and compositions as RAF kinase inhibitors
CA2962080A1 (en) * 2014-09-24 2016-03-31 Pain Therapeutics, Inc. 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
US20180185341A1 (en) 2014-10-03 2018-07-05 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
WO2016079669A1 (en) 2014-11-19 2016-05-26 Novartis Ag Labeled amino pyrimidine derivatives
WO2016088082A1 (en) 2014-12-05 2016-06-09 Novartis Ag Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
ES2756300T3 (es) 2014-12-16 2020-04-27 Novartis Ag Compuestos de ácido isoxazol hidroxámico como inhibidores de LpxC
SI3237418T1 (sl) 2014-12-23 2019-06-28 Novartis Ag Spojine triazolopirimidina in njihove uporabe
AU2016238436A1 (en) 2015-03-25 2017-08-17 Novartis Ag Formylated N-heterocyclic derivatives as FGFR4 inhibitors
EP3280795B1 (en) 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
EP3288948B1 (en) 2015-04-30 2019-11-20 Novartis AG Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors
EP3310813A1 (en) 2015-06-17 2018-04-25 Novartis AG Antibody drug conjugates
EP3297636B1 (en) * 2015-06-19 2021-02-17 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
AU2016284816B2 (en) * 2015-06-25 2021-10-07 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal composition and use thereof
CA2999268A1 (en) 2015-09-24 2017-03-30 Pain Therapeutics, Inc. Cocrystals of naloxone and naltrexone
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
MX2018005390A (es) 2015-11-13 2018-08-16 Novartis Ag Nuevos derivados de pirazolo pirimidina.
RS60946B1 (sr) 2015-11-26 2020-11-30 Novartis Ag Diamino piridinski derivati
CN105541701A (zh) * 2015-12-11 2016-05-04 吉林大学珠海学院 以顺丁烯二酸为前驱体的去铁酮药物共晶及其制备方法
CN105399665A (zh) * 2015-12-11 2016-03-16 吉林大学珠海学院 以对羟基苯甲酸为前驱体的去铁酮药物共晶及其制备方法
CN105399664A (zh) * 2015-12-11 2016-03-16 吉林大学珠海学院 以2,5-二羟基苯甲酸为前驱体的去铁酮药物共晶及其制备方法
HUP1500618A2 (en) 2015-12-16 2017-06-28 Druggability Tech Ip Holdco Ltd Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
WO2017103888A1 (en) 2015-12-18 2017-06-22 Novartis Ag Indane derivatives and the use thereof as soluble guanylate cyclase activators
EA201891439A1 (ru) 2015-12-18 2018-12-28 Новартис Аг Трициклические соединения и их композиции в качестве ингибиторов киназ
CA3012107A1 (en) 2016-01-21 2017-07-27 Novartis Ag Compounds and compositions for the treatment of cryptosporidiosis
BR112018016842A2 (pt) 2016-02-19 2018-12-26 Novartis Ag compostos de piridona tetracíclica como antivirais
US10590079B2 (en) 2016-03-01 2020-03-17 Novartis Ag Cyano-substituted indoles as LSD1 inhibitors
EP3426656B1 (en) 2016-03-08 2021-05-12 Novartis AG Tricyclic compounds useful to treat orthomyxovirus infections
WO2017163186A1 (en) 2016-03-24 2017-09-28 Novartis Ag Alkynyl nucleoside analogs as inhibitors of human rhinovirus
WO2017175185A1 (en) 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
IL263429B (en) 2016-06-20 2022-08-01 Novartis Ag Crystalline forms of a triazolopyrimidine compound
CN109790166A (zh) 2016-06-20 2019-05-21 诺华股份有限公司 咪唑并吡啶化合物用于治疗癌症
ES2798424T3 (es) 2016-06-20 2020-12-11 Novartis Ag Compuestos de triazolopiridina y usos de estos
CN106432136B (zh) * 2016-06-30 2018-12-25 中国药科大学 一种氢***和阿替洛尔共无定型***及其制备方法
AU2017298187B2 (en) 2016-07-20 2019-11-14 Novartis Ag Aminopyridine derivatives and their use as selective ALK-2 inhibitors
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
WO2018047109A1 (en) 2016-09-09 2018-03-15 Novartis Ag Polycyclic pyridone compounds as antivirals
WO2018047081A1 (en) 2016-09-09 2018-03-15 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
SG11201901146SA (en) 2016-09-23 2019-04-29 Novartis Ag Indazole compounds for use in tendon and/or ligament injuries
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
TW201819380A (zh) 2016-10-18 2018-06-01 瑞士商諾華公司 作為抗病毒劑之稠合四環吡啶酮化合物
JP2019534302A (ja) 2016-11-10 2019-11-28 ノバルティス アーゲー Ｂｍｐ増強剤
WO2018141749A1 (en) 2017-02-01 2018-08-09 Medivir Ab Therapeutic applications of malt1 inhibitors
US20180271837A1 (en) 2017-03-24 2018-09-27 Novartis Ag Isoxazole carboxamide compounds and uses thereof
AR111419A1 (es) 2017-04-27 2019-07-10 Novartis Ag Compuestos fusionados de indazol piridona como antivirales
AR111658A1 (es) 2017-05-05 2019-08-07 Novartis Ag 2-quinolinonas tricíclicas como agentes antibacteriales
UY37774A (es) 2017-06-19 2019-01-31 Novartis Ag Compuestos 5-cianoindol sustituidos y usos de los mismos
WO2019087163A1 (en) 2017-11-06 2019-05-09 Novartis Ag Polycyclic herg activators
WO2019087162A1 (en) 2017-11-06 2019-05-09 Novartis Ag Polycyclic herg activators
US20210079015A1 (en) 2017-11-17 2021-03-18 Novartis Ag Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
EA202091293A1 (ru) 2017-11-24 2020-11-23 Новартис Аг Производные пиридинона и их применение в качестве селективных ингибиторов alk-2
JP2021507906A (ja) 2017-12-20 2021-02-25 ノバルティス アーゲー 抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物
US11376253B2 (en) 2017-12-21 2022-07-05 Kyorin Pharmaceutical Co., Ltd. Agent for treating nocturnal pollakiuria
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
WO2019162429A1 (en) * 2018-02-23 2019-08-29 Center For Intelligent Research In Crystal Engineering, S.L. Cocrystals of ubiquinol and compositions comprising them
BR112020017121A2 (pt) 2018-02-28 2020-12-22 Novartis Ag Derivados de 10-(di(fenil)metil)-4-hidróxi-8,9,9a-10-tetra-hidro-7h-pirrolo[1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona e compostos relacionados como inibidores de da replicação de ortomixovírus para tratamento de influenza
WO2019166951A1 (en) 2018-02-28 2019-09-06 Novartis Ag Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
WO2019223632A1 (en) 2018-05-22 2019-11-28 Js Innomed Holdings Ltd. Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
JOP20200327A1 (ar) 2018-06-19 2020-12-15 Novartis Ag مركبات سيانوتريازول واستخداماتها
GB201811825D0 (en) 2018-07-19 2018-09-05 Benevolentai Bio Ltd Organic compounds
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
EP3837256B1 (en) 2018-08-17 2023-03-08 Novartis AG Urea compounds and compositions as smarca2/brm-atpase inhibitors
GB201813791D0 (en) 2018-08-23 2018-10-10 Benevolental Bio Ltd Organic compounds
JP7273951B2 (ja) 2018-09-12 2023-05-15 ノバルティス アーゲー 抗ウイルス性ピリドピラジンジオン化合物
BR112021005263A2 (pt) 2018-09-21 2021-06-15 Novartis Ag compostos de isoxazol carboxamida e usos dos mesmos
TW202028208A (zh) 2018-10-09 2020-08-01 瑞士商諾華公司 N-(4-氟-3-(6-(3-甲基吡啶-2-基)-[1,2,4]***并[1,5-a]嘧啶-2-基)苯基)-2,4-二甲基㗁唑-5-甲醯胺固體形式
CN113226464A (zh) 2018-12-18 2021-08-06 诺华股份有限公司 N-(吡啶-2-基磺酰基)环丙烷甲酰胺衍生物及其在治疗cftr介导的疾病中的用途
MX2021008303A (es) 2019-01-11 2021-10-13 Novartis Ag Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa.
US20220089592A1 (en) 2019-01-18 2022-03-24 Biogen Ma Inc. Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
WO2020154581A1 (en) * 2019-01-24 2020-07-30 Assia Chemical Industries Ltd Solid state forms of fedovapagon-salicyclic acid co-crystal
MX2021011289A (es) 2019-03-22 2021-11-03 Sumitomo Pharma Oncology Inc Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
CA3139634A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
AU2020304036A1 (en) 2019-06-27 2022-01-06 Biogen Ma Inc. 2H-indazole Derivatives and their use in the treatment of disease
MX2021015498A (es) 2019-06-27 2022-04-20 Biogen Ma Inc Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades.
KR20220028075A (ko) 2019-07-03 2022-03-08 스미토모 다이니폰 파마 온콜로지, 인크. 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
CN114341132A (zh) 2019-08-28 2022-04-12 诺华股份有限公司 经取代的1,3-苯基杂芳基衍生物及其在治疗疾病中的用途
TW202122078A (zh) 2019-09-06 2021-06-16 瑞士商諾華公司 使用lta4h抑制劑治療肝臟疾病之方法
KR20220070005A (ko) 2019-09-26 2022-05-27 노파르티스 아게 항바이러스성 피라졸로피리디논 화합물
JP2021054781A (ja) * 2019-09-26 2021-04-08 デボン エルエス，リミテッド 共結晶形エフィナコナゾール、及びその製造方法
UY38986A (es) 2019-12-18 2021-07-30 Novartis Ag Compuestos derivados de 3-(5-metoxi-1-oxoisoindolin-2-il) piperidin-2,6-diona, métodos de usos de los mismos y combinaciones farmacéuticas
MX2022008930A (es) 2020-01-22 2022-10-18 Benevolentai Bio Ltd Composiciones farmaceuticas y sus usos.
US20230149398A1 (en) 2020-01-22 2023-05-18 Benevolentai Bio Limited Topical pharmaceutical compositions comprising imidazo[1,2-b]pyridazine compounds
EP3884938A1 (en) 2020-03-25 2021-09-29 ArtemiFlow GmbH 1,2,4-trioxane compounds and compositions comprising the same for use in the treatment of covid-19
WO2021214080A1 (en) 2020-04-20 2021-10-28 Novartis Ag Antiviral 1,3-di-oxo-indene compounds
US20210322362A1 (en) 2020-04-20 2021-10-21 Novartis Ag Antiviral 1,3-di-oxo-indene compounds
CN113582927B (zh) * 2020-04-30 2023-07-04 苏州恩华生物医药科技有限公司 塞来昔布与普瑞巴林共无定型物及其制备方法
MX2022013856A (es) 2020-05-13 2023-04-05 Chdi Foundation Inc Moduladores htt para tratar la enfermedad de huntington.
WO2021253180A1 (en) 2020-06-15 2021-12-23 Novartis Ag Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators
JP2023531399A (ja) 2020-06-16 2023-07-24 ノバルティス アーゲー ＣＡＶ１．２活性化物質としてのメチル２－メチル－５－オキソ－１，４，５，７－テトラヒドロフロ［３，４－ｂ］ピリジン－３－カルボキシレート化合物
EP4214210A1 (en) 2020-09-17 2023-07-26 Novartis AG Compounds and compositions as sppl2a inhibitors
CN112552189A (zh) * 2020-11-10 2021-03-26 中国海洋大学 一种盐酸金刚烷胺与白藜芦醇的药物共晶及其制备方法
CN112521292B (zh) * 2020-12-18 2022-02-11 深圳市萱嘉生物科技有限公司 一种甜菜碱与有机酸的共晶及其制备方法、应用
EP4267576A1 (en) 2020-12-22 2023-11-01 Biogen MA Inc. Imidazo[1,2-a]pyridine derivatives as irak4 inhibitors and their use in the treatment of disease
AU2021409544A1 (en) 2020-12-22 2023-07-06 Biogen Ma Inc. 2h-indazole derivatives as irak4 inhibitors and their use in the treatment of disease
EP4274832A1 (en) 2021-01-07 2023-11-15 Biogen MA Inc. Tyk2 inhibitors
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.
EP4308559A1 (en) 2021-03-15 2024-01-24 Novartis AG Benzisoxazole derivatives and uses thereof
AR125196A1 (es) 2021-03-26 2023-06-21 Novartis Ag Derivados de ciclobutilo 1,3-sustituidos y sus usos
WO2022217232A1 (en) 2021-04-10 2022-10-13 Sunovion Pharmaceuticals Inc. Chromans and benzofurans as 5-ht1a and taar1 agonists
JP2024513918A (ja) 2021-04-10 2024-03-27 サノビオン ファーマシューティカルズ インク 置換スルホンアミド－クロマン化合物、ならびにその医薬組成物および使用方法
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
WO2022234287A1 (en) 2021-05-06 2022-11-10 Benevolentai Bio Limited Imidazopyridazine derivatives useful as trk inhibitors
EP4347596A1 (en) 2021-05-26 2024-04-10 Novartis AG Triazolo-pyrimidine analogues for treating diseases connected to the inhibiton of werner syndrome recq helicase (wrn)
KR20240013812A (ko) 2021-06-03 2024-01-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 의학적 용도
WO2023275796A1 (en) 2021-07-01 2023-01-05 Novartis Ag Heterocyclic derivatives as sphingosine-1-phosphate 3 inhibitors
CA3227169A1 (en) 2021-07-22 2023-01-26 Novartis Ag Substituted pyridone compounds useful to treat orthomyxovirus infections
WO2023049721A1 (en) 2021-09-23 2023-03-30 Sunovion Pharmaceuticals Inc. Methods of treating metabolic disorders
CN113845438B (zh) * 2021-10-12 2023-02-21 河北大学 一种对乙酰氨基酚-吡拉西坦药物共晶及其制备方法
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
CN114031515B (zh) * 2021-11-29 2022-10-21 河北大学 一种对乙酰氨基酚-布洛芬药物共晶及其制备方法
WO2023111799A1 (en) 2021-12-13 2023-06-22 Novartis Ag PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CaV1.2 ACTIVATORS
WO2023139534A1 (en) 2022-01-24 2023-07-27 Novartis Ag Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof
CN114644669A (zh) * 2022-03-10 2022-06-21 华润紫竹药业有限公司 一种***共晶体的制备方法及其应用
WO2023187715A1 (en) 2022-04-01 2023-10-05 Novartis Ag Complement factor b inhibitors and uses thereof
CN114835657A (zh) * 2022-06-10 2022-08-02 大连工业大学 一种基于离子液体调控乙水杨胺-糖精共晶多晶型的方法
WO2024006493A1 (en) 2022-07-01 2024-01-04 Biogen Ma Inc. Tyk2 inhibitors
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors
WO2024079623A1 (en) 2022-10-12 2024-04-18 Novartis Ag Tricyclic compounds and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8500862D0 (en) * 1985-01-14 1985-02-20 Tate & Lyle Plc Composition
HUP0201450A3 (en) * 1999-12-08 2003-02-28 Pharmacia Corp Chicago Solid-state form of celecoxib having enhanced bioavailability, pharmaceutical compositions containing it and their preparation
UA74539C2 (en) * 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
CA2396079A1 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
AU2002334987A1 (en) * 2001-10-15 2003-04-28 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
JP4906233B2 (ja) * 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ 少なくとも１種の有効薬剤成分を含有する多構成要素固相
AU2003272270A1 (en) * 2003-02-28 2004-09-28 The Regents Of The University Of Michigan Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883713B2 (en) 2001-06-22 2011-02-08 Aicuris Gmbh & Co. Kg Topical application of thiazolyl amides
US8784887B2 (en) 2005-03-30 2014-07-22 Aicuris Gmbh & Co. Kg Pharmaceutical preparation of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide
US7935817B2 (en) 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof

Also Published As

Publication number Publication date
EP1631260A2 (en) 2006-03-08
WO2004078163A3 (en) 2005-01-20
JP2007524596A (ja) 2007-08-30
WO2004078163A2 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
CA2514733A1 (en) Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2513746C (en) Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CN103596954B (zh) 苯甲酸利拉利汀的多晶型物
JP5017103B2 (ja) 薬剤共結晶組成物および関連した使用方法
US20070026078A1 (en) Pharmaceutical co-crystal compositions
US20070059356A1 (en) Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1552833B1 (en) Process for producing an amorphous optically active isomer of lansoprazole
JP2022088504A (ja) Ｌ－オルニチンフェニルアセテートおよびその製造方法
US20100311701A1 (en) Pharmaceutical Co-Crystal Compositions
ES2280892T3 (es) Composicion cristalina que contiene escitalopram.
JP2021512117A (ja) 嚢胞性線維症を処置するための医薬組成物
EP2822539B1 (en) Nanocrystalline solid dispersion compositions
LT4780B (lt) Živ proteazės inhibitoriaus rūgštusis sulfatas
US9884857B2 (en) Salts of dasatinib in amorphous form
US10828298B2 (en) Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide
CN106102716A (zh) 雄激素受体拮抗剂的固体药物组合物
ES2898878T3 (es) Cocristal de un inhibidor de la prolil·hidroxilasa de HIF disponible por vía oral
KR20150020683A (ko) 다사티닙 및 선택된 공-결정 형성제를 포함하는 다성분 결정
AU2004270238B2 (en) Modafinil compositions
JP6215940B2 (ja) ８−［（３ｒ）−３−アミノ−１−ピペリジニル］−７−（２−ブチン−１−イル）−３，７−ジヒドロ−３−メチル−１−［（４−メチル−２−キナゾリニル）メチル］−１ｈ−プリン−２，６−ジオンまたはその医薬的に許容され得る塩を含む安定な医薬組成物
CZ2016276A3 (cs) Pevné formy volné báze ibrutinibu
CA2858316A1 (en) Multicomponent crystalline system of voriconazole with fumaric acid
CN105358557A (zh) 化合物的多晶型物和盐
KR20040079936A (ko) 염기성 아미노산 ｉｉ를 함유하는 ｏ-아세틸살리실산의안정한 염
ALMARSSON et al. Patent 2514733 Summary

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20120803